Abstract
Cyclosporine (CsA) and MTX are commonly used for GVHD prophylaxis in pediatric allo-SCT. Mucositis and hepatic toxicity frequently restrict the delivery of the fourth dose of MTX. Folinic acid (FA) may ameliorate MTX toxicity. We conducted a retrospective chart review of all pediatric patients who received CsA and MTX for GVHD prophylaxis from January 2000 to July 2010. Patients treated before July 2007 (N=29) did not receive FA and those treated from July 2007 onward did receive FA (N=18). Patients who received FA were significantly more likely to receive day +11 MTX (odds ratio (OR) 10.42, 95% confidence interval (CI): 1.21–262.27) but there was no significant difference in Grade III–IV GVHD between the two groups (OR 1.15, 95% CI: 0.08–18.14). FA did not impact relapse-free survival (RFS) (P=0.82). Increased likelihood of receiving day +11 MTX suggests that FA ameliorates MTX toxicity, such as severe mucositis. FA administration for MTX GVHD prophylaxis should be studied in a prospective, randomized fashion.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Pasquini MC, Wang Z . Current use and outcome of hematopoietic stem cell transplantation: CIBMTR Summary Slides. 2010 Available at: http://www.cibmtr.org.
Deeg HJ, Storb R, Thomas ED, Flournoy N, Kennedy MS, Banaji M et al. Cyclosporine as prophylaxis for graft-versus-host disease: a randomized study in patients undergoing marrow transplantation for acute nonlymphoblastic leukemia. Blood 1985; 65: 1325–1334.
Storb R, Deeg HJ, Thomas ED, Appelbaum FR, Buckner CD, Cheever MA et al. Marrow transplantation for chronic myelocytic leukemia: a controlled trial of cyclosporine versus methotrexate for prophylaxis of graft-versus-host disease. Blood 1985; 66: 698–702.
Irle C, Deeg HJ, Buckner CD, Kennedy M, Clift R, Storb R et al. Marrow transplantation for leukemia following fractionated total body irradiation. A comparative trial of methotrexate and cyclosporine. Leuk Res 1985; 9: 1255–1261.
Deeg HJ, Storb R, Weiden PL, Raff RF, Sale GE, Atkinson K et al. Cyclosporin A and methotrexate in canine marrow transplantation: engraftment, graft-versus-host disease, and induction of intolerance. Transplantation 1982; 34: 30–35.
Deeg HJ, Storb R, Appelbaum FR, Kennedy MS, Graham TC, Thomas ED . Combined immunosuppression with cyclosporine and methotrexate in dogs given bone marrow grafts from DLA-haploidentical littermates. Transplantation 1984; 37: 62–65.
Storb R, Deeg HJ, Whitehead J, Appelbaum F, Beatty P, Bensinger W et al. Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia. N Engl J Med 1986; 314: 729–735.
Gratwohl AA, Bull MI, Graw RG, Norton L, Knutsen T . Methotrexate and citrovorum factor after histoincompatible allogeneic bone marrow transplants in dogs. Acta Haematol 1978; 60: 233–242.
Torres A, Martinez F, Gomez P, Herrera C, Rojas R, Gomez-Villagran JL et al. Cyclosporin A versus methotrexate, followed by rescue with folinic acid as prophylaxis of acute graft-versus-host disease after bone marrow transplantation. Blut 1989; 58: 63–68.
Nevill TJ, Tirgan MH, Deeg HJ, Klingemann HG, Reece DE, Shepherd JD et al. Influence of post-methotrexate folinic acid rescue on regimen-related toxicity and graft-versus-host disease after allogeneic bone marrow transplantation. Bone Marrow Transplant 1992; 9: 349–354.
Russell JA, Woodman RC, Poon MC, Jones AR, Ruether BA . Addition of low-dose folinic acid to a methotrexate/cyclosporin A regimen for prevention of acute graft-versus-host disease. Bone Marrow Transplant 1994; 14: 397–401.
Ruutu T, Niederwieser D, Gratwohl A, Apperley JF . A survey of the prophylaxis and treatment of acute GVHD in Europe: a report of the European Group for Blood and Marrow, Transplantation (EBMT). Chronic Leukaemia Working Party of the EBMT. Bone Marrow Transplant 1997; 19: 759–764.
Bhurani D, Schifter M, Kerridge I . Folinic acid administrations following MTX as prophylaxis for GVHD in allogeneic HSCT centres in Australia and New Zealand. Bone Marrow Transplant 2008; 42: 547–550.
Peters C, Minkov M, Gadner H, Klingebiel T, Vossen J, Locatelli F et al. European Group for Blood and Marrow Transplantation (EBMT) Working Party Paediatric Diseases; International BFM Study Group--Subcommittee Bone Marrow Transplantation (IBFM-SG). Statement of current majority practices in graft-versus-host disease prophylaxis and treatment in children. Bone Marrow Transplant 2000; 26: 405–411.
Storb R, Antin JH, Cutler C . Should methotrexate plus calcineurin inhibitors be considered standard of care for prophylaxis of acute graft-versus-host disease? Biol Blood Marrow Transplant 2010; 16: S18–S27.
Ratanatharathorn V, Nash RA, Przepiorka D, Devine SM, Klein JL, Weisdorf D et al. Phase III study comparing methotrexate and tacrolimus (prograf, FK506) with methotrexate and cyclosporine for graft-versus-host disease prophylaxis after HLA-identical sibling bone marrow transplantation. Blood 1998; 92: 2303–2314.
Nash RA, Antin JH, Karanes C, Fay JW, Avalos BR, Yeager AM et al. Phase 3 study comparing methotrexate and tacrolimus with methotrexate and cyclosporine for prophylaxis of acute graft-versus-host disease after marrow transplantation from unrelated donors. Blood 2000; 96: 2062–2068.
Nash RA, Pepe MS, Storb R, Longton G, Pettinger M, Anasetti C et al. Acute graft-versus-host disease: analysis of risk factors after allogeneic marrow transplantation and prophylaxis with cyclosporine and methotrexate. Blood 1992; 80: 1838–1845.
Kumar S, Wolf RC, Chen MG, Gastineau DA, Gertz MA, Inwards DJ et al. Omission of day +11 methotrexate after allogeneic bone marrow transplantation is associated with increased risk of severe acute graft-versus-host disease. Bone Marrow Transplant 2002; 31: 73–75.
Przepiorka D, Weisdorf D, Martin P, Klingemann HG, Beatty P, Hows J et al. Consensus conference on acute GVHD grading. Bone Marrow Transplant 1995; 15: 825–828.
Atkinson K, Downs K . Omission of day 11 methotrexate does not appear to influence the incidence of moderate to severe graft versus host disease, relapse rate, or survival after HLA-identical sibling bone marrow transplantation. Bone Marrow Transplant 1995; 16: 755–758.
Yanik G, Levine JE, Ratanatharathorn V, Dunn R, Ferrara J, Hutchinson RJ . Tacrolimus and methotrexate as prophylaxis for acute graft-versus-host disease in pediatric allogeneic stem cell transplantation. Bone Marrow Transplant 2000; 26: 161–167.
Sugita J, Matsushita T, Kashiwazaki H, Kosugi M, Takahashi S, Wakasa K et al. Efficacy of folinic acid on preventing oral mucositis in allogeneic stem cell transplant patients receiving MTX as prophylaxis for GVHD. Bone Marrow Transplant 2012; 47: 258–264.
Robien K, Schubert MM, Yasui Y, Martin P, Storb R, Potter JD et al. Folic acid supplementation during methotrexate immunosuppression is not assoiciated with early toxicity, risk of acute graft-versus-host-disease or relapse following hematopoietic transplantation. Bone Marrow Transplant 2006; 37: 687–692.
Ulrich C, Yasui Y, Storb R, Schubert M, Wagner JL, Bigler J . Pharmacogenetics of methotrexate: toxicity among marrow transplantation patients varies with the methylenetetrahydrofolate reductase C677T polymorphism. Blood 2001; 98: 231–234.
Robien K, Schubert MM, Chay T, Bigler J, Storb R, Yasui Y et al. Methylenetetrahydrofolate reductase and thymidylate synthase genotypes modify oral mucositis severity following hematopoietic stem cell transplantation. Bone Marrow Transplant 2006; 37: 799–800.
Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R et al. Donor methylenetetrahydrofolate reducatse genotype is associated with graft-versus-host disease in hematopoietic stem cell transplant patients treated with methotrexate. Bone Marrow Transplant 2006; 37: 773–779.
Murphy N, Diviney M, Szer J, Bardy P, Grigg A, Hoyt R et al. The effect of folinic acid on methylenetetrahydrofolate reductase polymorphisms in methotrexate-treated allogeneic hematopoietic stem cell transplants. Biol Blood Marrow Transplant 2012; 18: 722–730.
Bolwell B, Sobecks R, Pohlman B, Andresen S, Rybicki L, Kuczkowski E et al. A prospective randomized trial comparing cyclosporine and short course methotrexate with cyclosporine and mycophenolate mofetil for GVHD prophylaxis in myeloablative allogeneic bone marrow transplantation. Bone Marrow Transplant 2004; 34: 621–625.
Perkins J, Field T, Kim J, Kharfan-Dabaja M, Fernandez H, Ayala E et al. A randomized phase II trial comparing tacrolimus and mycophenolate mofetil to tacrolimus and methotrexate for acute graft-versus-host disease prophylaxis. Biol Blood Marrow Transplant 2010; 16: 937–947.
Ohata K, Espinoza JL, Lu X, Kondo Y, Nakao S . Mycophenolic acid inhibits natural killer cell proliferation and cytotoxic function: a possible disadvantage of including mycophenolate mofetil in the graft-versus-host disease prophylaxis regimen. Biol Blood Marrow Transplant 2011; 17: 205–213.
Leung W . Use of NK cell activity in cure of transplant. Br J Haematol 2011; 155: 14–29.
Acknowledgements
Supported in part by the Biostatistics Shared Resource, Hollings Cancer Center, Medical University of South Carolina (P30 CA138313).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Hudspeth, M., Heath, T., Chiuzan, C. et al. Folinic acid administration after MTX GVHD prophylaxis in pediatric allo-SCT. Bone Marrow Transplant 48, 46–49 (2013). https://doi.org/10.1038/bmt.2012.82
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2012.82
Keywords
This article is cited by
-
Curative potential of fludarabine, melphalan, and non-myeloablative dosage of busulfan in elderly patients with myeloid malignancy
International Journal of Hematology (2020)
-
Breakthrough infection of Geotrichum capitatum during empirical caspofungin therapy after umbilical cord blood transplantation
International Journal of Hematology (2018)
-
Folinic acid after MTX as prophylaxis for GVHD in pediatric bone marrow transplantation
International Journal of Hematology (2015)